United Therapeutics Corporation $UTHR Position Trimmed by Barclays PLC

Barclays PLC decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,846 shares of the biotechnology company’s stock after selling 1,914 shares during the period. Barclays PLC owned about 0.26% of United Therapeutics worth $47,306,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. AXQ Capital LP grew its holdings in shares of United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC raised its holdings in shares of United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC raised its holdings in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Optimize Financial Inc acquired a new stake in United Therapeutics during the third quarter valued at $444,000. Finally, Simplify Asset Management Inc. acquired a new stake in United Therapeutics during the third quarter valued at $8,351,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on UTHR. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $539.00.

United Therapeutics Stock Up 10.7%

United Therapeutics stock opened at $529.17 on Tuesday. The business has a 50 day moving average price of $483.03 and a two-hundred day moving average price of $455.82. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $537.19. The stock has a market cap of $23.19 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.72 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $6.19 EPS. On average, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $483.16, for a total transaction of $4,010,228.00. Following the completion of the transaction, the executive vice president directly owned 36,844 shares of the company’s stock, valued at approximately $17,801,547.04. This trade represents a 18.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 2,000 shares of United Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the sale, the director owned 8,480 shares in the company, valued at approximately $4,150,281.60. This trade represents a 19.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 329,497 shares of company stock valued at $160,170,312. 10.30% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.